Powering Down Malaria in African Kids with Chemoprevention

Malaria still kills many children under five across Africa. It is the biggest cause of illness and death in that age group. To fight this, health workers rely on chemoprevention methods. Two main approaches are perennial malaria chemoprevention (PMC) and seasonal malaria chemoprevention (SMC). These are part of a broader set of preventive actions. A recent scoping review looked at how well these strategies work and what helps them succeed in different places.

The researchers searched several databases for studies published between 2002 and October 2025. They focused on peer‑reviewed quantitative research. After screening, they kept 42 studies out of 386 that were found. The coverage for both PMC and SMC stayed in the 50‑60 % range across all doses. Kids were more likely to take the first dose than later ones. This pattern shows a drop‑off in adherence as the regimen continues.

When it comes to protecting kids, PMC reduced risk by 20 % to 87.5 % in various settings. SMC was even stronger, cutting risk by about 88 %. Adding the RTS,S/AS01E vaccine to chemoprevention made the protection even better. Several factors changed how well the strategies worked. High seasonal transmission, hidden asymptomatic infections, and intense local spread all influenced outcomes. Understanding these variables helps tailor programs to local needs.

Overall, malaria chemoprevention proves useful for lowering the disease burden in young children. The biggest gains appear when the methods are paired with vaccination. Combining tools seems to give the strongest shield against malaria. This insight guides policymakers and field workers as they plan interventions across the continent.